MF280

**MF280** is a selective CD28 inhibitor developed as an immunosuppressive agent. CD28 is a co-stimulatory receptor on T cells critical for T cell activation and proliferation; by blocking CD28 signaling, MF280 prevents T cell responses while sparing regulatory T cells, offering a targeted approach to immunosuppression with potentially reduced broad toxicity compared to non-selective agents. Initially developed by Effimune SA, a company focused on immune system diseases, it represents an early biotech innovation in selective immunomodulation. Its precise primary indications remain unspecified in available data, but it aligns with applications in transplantation or autoimmune disorders where T cell inhibition is beneficial.